NASDAQ:EYEGEyegate Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Eyegate Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.17 +0.07 (+1.37 %) (As of 06/2/2020 04:00 PM ET) Add Compare Share Today's Range$5.02Now: $5.17▼$5.1750-Day Range$4.80MA: $5.31▼$5.8952-Week Range$2.25Now: $5.17▼$12.89Volume21,300 shsAverage Volume77,276 shsMarket Capitalization$23.92 millionP/E RatioN/ADividend YieldN/ABeta1.67 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system. The company's CMHA-S based product, the EyeGate Ocular Bandage Gel, a topically-applied eye drop formulation that has completed its first-in-man clinical trial for the management of corneal epithelial wounds/defects and epitheliopathies, as well as to accelerate re-epithelization of the ocular surface following surgery, injection, and other traumatic and non-traumatic conditions. It is also developing EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients; and anterior uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and ciliary body, as well as Eyegate II drug delivery system. The company has license agreements with the University of Miami and its School of Medicine; subsidiaries of Valeant Pharmaceuticals International, Inc.; BioTime, Inc.; and the University of Utah Research Foundation. Eyegate Pharmaceuticals, Inc. is headquartered in Waltham, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingEyegate Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.00, Eyegate Pharmaceuticals has a potential upside of 132.1% from its current price of $5.17.Amount of Analyst CoverageEyegate Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesEyegate Pharmaceuticals has received 426 “outperform” votes. (Add your “outperform” vote.)Underperform VotesEyegate Pharmaceuticals has received 356 “underperform” votes. (Add your “underperform” vote.)Community SentimentEyegate Pharmaceuticals has received 54.48% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Eyegate Pharmaceuticals and other stocks. Vote “Outperform” if you believe EYEG will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EYEG will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldEyegate Pharmaceuticals does not currently pay a dividend.Dividend GrowthEyegate Pharmaceuticals does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Eyegate Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders47.50% of the stock of Eyegate Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions42.32% of the stock of Eyegate Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Eyegate Pharmaceuticals are expected to grow in the coming year, from ($2.17) to ($1.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eyegate Pharmaceuticals is -1.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eyegate Pharmaceuticals is -1.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEyegate Pharmaceuticals has a P/B Ratio of 3.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.77 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EYEG Previous Symbol CUSIPN/A CIK1372514 Webwww.eyegatepharma.com Phone781-788-8869Debt Debt-to-Equity RatioN/A Current Ratio8.05 Quick Ratio8.05Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.69 million Price / Sales8.89 Cash FlowN/A Price / Cash FlowN/A Book Value$1.64 per share Price / Book3.15Profitability EPS (Most Recent Fiscal Year)($2.23) Net Income$-7,100,000.00 Net MarginsN/A Return on Equity-133.93% Return on Assets-94.32%Miscellaneous Employees11 Outstanding Shares4,627,000Market Cap$23.92 million Next Earnings Date8/13/2020 (Estimated) OptionableNot Optionable NASDAQ:EYEG Rates by TradingView Receive EYEG News and Ratings via Email Sign-up to receive the latest news and ratings for EYEG and its competitors with MarketBeat's FREE daily newsletter. Eyegate Pharmaceuticals (NASDAQ:EYEG) Frequently Asked Questions How has Eyegate Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Eyegate Pharmaceuticals' stock was trading at $5.03 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, EYEG stock has increased by 2.8% and is now trading at $5.17. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Eyegate Pharmaceuticals? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyegate Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Eyegate Pharmaceuticals. When is Eyegate Pharmaceuticals' next earnings date? Eyegate Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Eyegate Pharmaceuticals. How were Eyegate Pharmaceuticals' earnings last quarter? Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) posted its quarterly earnings results on Wednesday, May, 6th. The specialty pharmaceutical company reported ($0.43) earnings per share for the quarter. View Eyegate Pharmaceuticals' earnings history. What price target have analysts set for EYEG? 1 Wall Street analysts have issued 12-month price objectives for Eyegate Pharmaceuticals' shares. Their forecasts range from $12.00 to $12.00. On average, they expect Eyegate Pharmaceuticals' share price to reach $12.00 in the next year. This suggests a possible upside of 132.1% from the stock's current price. View analysts' price targets for Eyegate Pharmaceuticals. Has Eyegate Pharmaceuticals been receiving favorable news coverage? News headlines about EYEG stock have been trending neutral this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Eyegate Pharmaceuticals earned a news sentiment score of 0.2 on InfoTrie's scale. They also assigned news stories about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutEyegate Pharmaceuticals. Are investors shorting Eyegate Pharmaceuticals? Eyegate Pharmaceuticals saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 15,100 shares, a drop of 9.6% from the April 30th total of 16,700 shares. Based on an average daily volume of 81,700 shares, the short-interest ratio is currently 0.2 days. Approximately 0.3% of the company's shares are sold short. View Eyegate Pharmaceuticals' Current Options Chain. Who are some of Eyegate Pharmaceuticals' key competitors? Some companies that are related to Eyegate Pharmaceuticals include TFF Pharmaceuticals (TFFP), Corvus Pharmaceuticals (CRVS), Leap Therapeutics (LPTX), Genprex (GNPX), Oncolytics Biotech (ONCY), Catalyst Biosciences (CBIO), CannTrust (CTST), Aptorum Group (APM), CTI BioPharma (CTIC), Bellerophon Therapeutics (BLPH), CV Sciences (CVSI), Sesen Bio (SESN), Clearside Biomedical (CLSD), Celsion (CLSN) and Onconova Therapeutics (ONTX). View all competitors. What other stocks do shareholders of Eyegate Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Eyegate Pharmaceuticals investors own include Bausch Health Companies (BHC), MannKind (MNKD), Sorrento Therapeutics (SRNE), Novavax (NVAX), Celldex Therapeutics (CLDX), Gilead Sciences (GILD), Idera Pharmaceuticals (IDRA), Arca Biopharma (ABIO), SCYNEXIS (SCYX) and Synergy Pharmaceuticals (SGYP). Who are Eyegate Pharmaceuticals' key executives? Eyegate Pharmaceuticals' management team includes the following people: Mr. Stephen From, Pres, CEO & Director (Age 56)Dr. Barbara M. Wirostko, Chief Medical Officer (Age 53)Mr. Michael P. Manzo, VP of Engineering (Age 60)Ms. Sarah Romano, Chief Financial OfficerDr. MaryJane Rafii Ph.D., Consultant When did Eyegate Pharmaceuticals IPO? (EYEG) raised $5 million in an IPO on Friday, February 13th 2015. The company issued 800,000 shares at a price of $6.00 per share. Aegis Capital Corp and Chardan Capital Markets served as the underwriters for the IPO. What is Eyegate Pharmaceuticals' stock symbol? Eyegate Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYEG." How do I buy shares of Eyegate Pharmaceuticals? Shares of EYEG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Eyegate Pharmaceuticals' stock price today? One share of EYEG stock can currently be purchased for approximately $5.17. How big of a company is Eyegate Pharmaceuticals? Eyegate Pharmaceuticals has a market capitalization of $23.92 million and generates $2.69 million in revenue each year. The specialty pharmaceutical company earns $-7,100,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis. Eyegate Pharmaceuticals employs 11 workers across the globe. What is Eyegate Pharmaceuticals' official website? The official website for Eyegate Pharmaceuticals is www.eyegatepharma.com. How can I contact Eyegate Pharmaceuticals? Eyegate Pharmaceuticals' mailing address is 271 WAVERLEY OAKS ROAD SUITE 108, WALTHAM MA, 02452. The specialty pharmaceutical company can be reached via phone at 781-788-8869. This page was last updated on 6/3/2020 by MarketBeat.com Staff
